Wretlind, Asger
Curovic, Viktor Rotbain
de Zawadzki, Andressa
Suvitaival, Tommi
Xu, Jin
Zobel, Emilie Hein
von Scholten, Bernt Johan
Ripa, Rasmus Sejersten
Kjaer, Andreas
Hansen, Tine Willum
Vilsbøll, Tina
Vestergaard, Henrik
Rossing, Peter
Legido-Quigley, Cristina
Article History
Received: 4 July 2023
Accepted: 11 September 2023
First Online: 26 September 2023
Declarations
:
: Both trials were approved by regional ethics committee and the Danish Medicine Agency and followed the principles laid out by the Declaration of Helsinki and Good Clinical Practice. Participants provided written informed consent before their enrollment in the study.
: The authors declare no conflict of interest compromising the integrity of this work.Disclosures outside this work: EZ and BJvS are now employees at Novo Nordisk and have shares in Novo Nordisk. RR has served as consultant for Novo Nordisk and has shares in Novo Nordisk. AK has served on advisory boards or as consultant for Novo Nordisk, Curium, Clarity Pharmaceuticals, IPSEN, and Siemens Healthineers. TH own shares in Novo Nordisk. TV has served on scientific advisory panels, been part of speaker's bureaus, served as a consultant to and/or received research support from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Gilead, GSK, Mundipharma, Novo Nordisk, Sanofi and Sun Pharmaceuticals. PR has received honoraria for consultancy to Steno Diabetes Center Copenhagen from Astellas, Astra Zeneca, Boehringer Ingelheim, Bayer, Merck, Gilead, Novo Nordisk, Sanofi Aventis. CLQ has served on scientific advisory panels and/or received research support from Pfizer, Novo Nordisk and other companies via the IMI funding scheme.